The topic of drug pricing is all the rage these days. The general opinion is that overall spending on legal drugs, i.e. pharmaceuticals, is "too high," or alternatively that prices of individual drugs are too high, and I'll explore those similar concepts in this article....
READ MORE
|
The first deuterated drug has finally been approved by the FDA. It’s Austedo (deutetrabenazine), from Teva (NYSE:TEVA), and it targets Huntington’s chorea. This is an interesting development on several levels....
READ MORE
|
Medicare Part D is costing taxpayers more than $10 billion dollars a year in excess reimbursements relative to the Federal Supply Schedule used by other agencies for the same drugs....
READ MORE
|
The pharma and biotech industry has been hit badly by concerns over high drug prices in the past few years. The initial panic was triggered in September 2015 when the Democratic presidential candidate Hillary Clinton tweeted about "price gouging" and laid out a proposal for combating skyrocketing drug prices....
READ MORE
|
I’m no pharma/biotech guru. I do, however, live in San Diego, which gives me access to a plethora of information on the local companies in this industry....
READ MORE
|